Gene Co-Expression Networks Restructured Gene Fusion in Rhabdomyosarcoma Cancers
暂无分享,去创建一个
Kun Huang | Jie Zhang | Zhi Han | Xiaohui Zhan | Zhi Han | Jie Zhang | Kun Huang | K. Pollok | Dong Ni | Bryan R Helm | Michael J Ferguson | J. Renbarger | Dong Ni | Pankita H Pandya | Mary E Murray | Karen E Pollok | Jamie L Renbarger | P. Pandya | M. Murray | Xiaohui Zhan
[1] S. Fulda,et al. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis , 2018, Oncogene.
[2] Lynette M. Smith,et al. Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. , 2006, The Journal of molecular diagnostics : JMD.
[3] F. Barr,et al. Tumorigenesis and Neoplastic Progression High Expression of the PAX3-FKHR Oncoprotein Is Required to Promote Tumorigenesis of Human Myoblasts , 2022 .
[4] Lynette M. Smith,et al. Genomic and Clinical Analysis of Amplification of the 13q31 Chromosomal Region in Alveolar Rhabdomyosarcoma: A Report from the Children's Oncology Group , 2011, Clinical Cancer Research.
[5] P. Meltzer,et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. , 2011, Cancer research.
[6] M. Delorenzi,et al. Reply to S. Stegmaier et al , 2012 .
[7] T. Triche,et al. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. , 2006, Cancer research.
[8] Kun Huang,et al. Normalized lmQCM: An Algorithm for Detecting Weak Quasi-Cliques in Weighted Graph with Applications in Gene Co-Expression Module Discovery in Cancers , 2014, Cancer informatics.
[9] Lynette M. Smith,et al. Genomic and clinical analyses of 2p24 and 12q13‐q14 amplification in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group , 2009, Genes, chromosomes & cancer.
[10] H. Enterline,et al. Rhabdomyosarcoma: A clinicopathological study and classification of 39 cases , 1958, Cancer.
[11] M. Cieśla,et al. MicroRNAs and epigenetic mechanisms of rhabdomyosarcoma development. , 2014, The international journal of biochemistry & cell biology.
[12] S. Horvath,et al. A General Framework for Weighted Gene Co-Expression Network Analysis , 2005, Statistical applications in genetics and molecular biology.
[13] Mauro Delorenzi,et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Holly S Stevenson,et al. Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma , 2015, Modern Pathology.
[15] O. Delattre,et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Yang Xiang,et al. Mining the tissue-tissue gene co-expression network for tumor microenvironment study and biomarker prediction , 2013, BMC Genomics.
[17] G. Grosveld,et al. PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis. , 2013, Neoplasia.
[18] Steve Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[19] Sean R. Davis,et al. GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor , 2007, Bioinform..
[20] Chang S. Chan,et al. Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers , 2014, Molecular Cancer Research.
[21] Raphael Gottardo,et al. Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.
[22] G. Getz,et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.
[23] S. Bielack,et al. Questionable universal validity of PAX3/FOXO1 fusion gene status as molecular marker for improvement of risk stratification in rhabdomyosarcoma therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] M. Ferrer,et al. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. , 2017, Cancer discovery.
[25] M. Bittner,et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. , 1998, Cancer research.
[26] E. Monti,et al. Uncovering metabolism in rhabdomyosarcoma , 2016, Cell cycle.
[27] Cun-Quan Zhang,et al. A new clustering method and its application in social networks , 2011, Pattern Recognit. Lett..
[28] Edda Klipp,et al. Supporting Text S1: Influence of cell shape, inhomogeneities and diffusion barriers in cell polarization models , 2015 .
[29] P. Meltzer,et al. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion‐positive and fusion‐negative rhabdomyosarcoma , 2019, International journal of cancer.
[30] G. Getz,et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.
[31] D. Januszkiewicz-Lewandowska,et al. Rhabdomyosarcoma in children - current pathologic and molecular classification. , 2018, Polish journal of pathology : official journal of the Polish Society of Pathologists.
[32] S. Spunt,et al. Pediatric nonrhabdomyosarcoma soft tissue sarcomas. , 2008, The oncologist.
[33] J. Davie,et al. New insights into signalling-pathway alterations in rhabdomyosarcoma , 2014, British Journal of Cancer.
[34] Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements , 2017, Genome Biology.
[35] Elizabeth Stewart,et al. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. , 2018, Cancer cell.
[36] Federica Conte,et al. Network-Based Approaches to Explore Complex Biological Systems towards Network Medicine , 2018, Genes.
[37] G. Camussi,et al. The PAX3-FOXO1 Fusion Protein Present in Rhabdomyosarcoma Interferes with Normal FOXO Activity and the TGF-β Pathway , 2015, PloS one.
[38] J. Houghton,et al. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] A. Ferrari,et al. Rhabdomyosarcoma , 2019, Nature Reviews Disease Primers.
[40] J. Khan,et al. PAX3–FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma , 2017, The Journal of pathology.
[41] F. Barr,et al. Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances. , 2007, Current molecular medicine.
[42] B. Johansson,et al. The impact of translocations and gene fusions on cancer causation , 2007, Nature Reviews Cancer.
[43] Yang Xiang,et al. Weighted Frequent Gene Co-expression Network Mining to Identify Genes Involved in Genome Stability , 2012, PLoS Comput. Biol..
[44] Peter Langfelder,et al. Eigengene networks for studying the relationships between co-expression modules , 2007, BMC Systems Biology.
[45] Cesare Furlanello,et al. Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3‐FKHR positive and negative tumors , 2006, International journal of cancer.
[46] F. Barr,et al. Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma , 2018, Molecules.
[47] Daniel J. Devine,et al. Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. , 2018, Cancer cell.
[48] Satoru Miyano,et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma , 2015, Nature Communications.
[49] J. Khan,et al. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma , 2017, eLife.
[50] James R. Anderson,et al. Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V , 2001, Journal of pediatric hematology/oncology.
[51] C. Linardic. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. , 2008, Cancer letters.